Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

A multicentre validation study of the diagnostic value of plasma neurofilament light.

Open access

Published version of a preprint

Abstract

Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as a marker of neurodegeneration in 13 neurodegenerative disorders, Down syndrome, depression and cognitively unimpaired controls from two multicenter cohorts: King’s College London ( n = 805) and the Swedish BioFINDER study ( n = 1,464). Plasma NfL was significantly increased in all cortical neurodegenerative disorders, amyotrophic lateral sclerosis and atypical parkinsonian disorders. We demonstrate that plasma NfL is clinically useful in identifying atypical parkinsonian disorders in patients with parkinsonism, dementia in individuals with Down syndrome, dementia among psychiatric disorders, and frontotemporal dementia in patients with cognitive impairment. Data-driven cut-offs highlighted the fundamental importance of age-related clinical cut-offs for disorders with a younger age of onset. Finally, plasma NfL performs best when applied to indicate no underlying neurodegeneration, with low false positives, in all age-related cut-offs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-23620-z

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The concentrations of plasma NfL for different diagnostic and controls groups in the KCL and Lund cohorts. Plasma neurofilament light (NfL) in different diagnostic groups; KCL (A n = 805) and Lund (B n = 1464) cohorts. For each plot, the horizontal bar shows the median, and the upper and lower boundaries show the 25th and 75th percentiles, respectively. Source data are provided as a Source Data file. KCL Cohort—AD Alzheimer’s disease (n = 102), ALS amyotrophic lateral sclerosis (n = 50), CU Aβ− cognitively unimpaired without Aβ pathology (n = 130), CU Aβ+ cognitively unimpaired with Aβ pathology (n = 28), CBS/PSP corticobasal syndrome and progressive supranuclear palsy (n = 19), depression (n = 37), DS Down syndrome (n = 29), DSAD Down syndrome Alzheimer’s disease (n = 12), EOAD early-onset Alzheimer’s disease (n = 59), FTD frontotemporal dementia (n = 54), MCI Aβ− mild cognitive impairment without Aβ pathology (n = 55), MCI Aβ+ mild cognitive impairment with Aβ pathology (n = 31), PD Parkinson’s disease (n = 140), PDD/DLB Parkinson’s disease dementia and dementia with Lewy bodies (n = 59). Lund Cohort—AD Alzheimer’s disease (n = 134), CU Aβ− cognitively unimpaired without Aβ pathology (n = 273), CU Aβ+ cognitively unimpaired with Aβ pathology (n = 103), CBS/PSP corticobasal syndrome and progressive supranuclear palsy (n = 24), EOAD early-onset Alzheimer’s disease (n = 23), FTD frontotemporal dementia (n = 150), MCI Aβ− mild cognitive impairment without Aβ pathology (n = 115), MCI Aβ+ mild cognitive impairment with Aβ pathology (n = 165), MSA multiple system atrophy (n = 29), PD Parkinson’s disease (n = 171), PDD/DLB Parkinson’s disease dementia and dementia with Lewy bodies (n = 46), SCD Aβ− subjective cognitive decline without Aβ pathology (n = 134), SCD Aβ+ subjective cognitive decline with Aβ pathology (n = 75), VaD vascular dementia (n = 22).
Fig. 1 The concentrations of plasma NfL for different diagnostic and controls groups in the KCL and Lund cohorts. Plasma neurofilament light (NfL) in different diagnostic groups; KCL (A n = 805) and Lund (B n = 1464) cohorts. For each plot, the horizontal bar shows the median, and the upper and lower boundaries show the 25th and 75th percentiles, respectively. Source data are provided as a Source Data file. KCL Cohort—AD Alzheimer’s disease (n = 102), ALS amyotrophic lateral sclerosis (n = 50), CU Aβ− cognitively unimpaired without Aβ pathology (n = 130), CU Aβ+ cognitively unimpaired with Aβ pathology (n = 28), CBS/PSP corticobasal syndrome and progressive supranuclear palsy (n = 19), depression (n = 37), DS Down syndrome (n = 29), DSAD Down syndrome Alzheimer’s disease (n = 12), EOAD early-onset Alzheimer’s disease (n = 59), FTD frontotemporal dementia (n = 54), MCI Aβ− mild cognitive impairment without Aβ pathology (n = 55), MCI Aβ+ mild cognitive impairment with Aβ pathology (n = 31), PD Parkinson’s disease (n = 140), PDD/DLB Parkinson’s disease dementia and dementia with Lewy bodies (n = 59). Lund Cohort—AD Alzheimer’s disease (n = 134), CU Aβ− cognitively unimpaired without Aβ pathology (n = 273), CU Aβ+ cognitively unimpaired with Aβ pathology (n = 103), CBS/PSP corticobasal syndrome and progressive supranuclear palsy (n = 24), EOAD early-onset Alzheimer’s disease (n = 23), FTD frontotemporal dementia (n = 150), MCI Aβ− mild cognitive impairment without Aβ pathology (n = 115), MCI Aβ+ mild cognitive impairment with Aβ pathology (n = 165), MSA multiple system atrophy (n = 29), PD Parkinson’s disease (n = 171), PDD/DLB Parkinson’s disease dementia and dementia with Lewy bodies (n = 46), SCD Aβ− subjective cognitive decline without Aβ pathology (n = 134), SCD Aβ+ subjective cognitive decline with Aβ pathology (n = 75), VaD vascular dementia (n = 22).CC BY · PubMed Central
Fig. 2 Effect sizes of neurodegenerative disorders as compared to amyloid-negative cognitively unimpaired controls, Parkinson’s disease and Alzheimer’s disease. Effect sizes (Hedges’s g) of different neurodegenerative disorders as compared to amyloid-negative cognitively unimpaired controls (A n = 403), Parkinson’s disease (B n = 311), and Alzheimer’s disease (C n = 236). The bars represent the mean effect size for the cohort, whereas the error bars represent the standard deviation of effect size when considering the KCL and Lund cohorts separately. Those without error bars (e.g., VaD) are only included in one cohort. AD Alzheimer’s disease (n = 236), ALS amyotrophic lateral sclerosis (n = 50), CU Aβ− cognitively unimpaired without Aβ pathology (n = 403), CBS/PSP corticobasal syndrome and progressive supranuclear palsy (n = 43), depression (n = 37), DS Down syndrome (n = 29), DSAD Down syndrome Alzheimer’s disease (n = 12), EOAD early-onset Alzheimer’s disease (n = 82), FTD frontotemporal dementia (n = 204), MCI Aβ− mild cognitive impairment without Aβ pathology (n = 170), MCI Aβ + mild cognitive impairment with Aβ pathology (n = 196), MSA multiple system atrophy (n = 29), PD Parkinson’s disease (n = 311), PDD/DLB Parkinson’s disease dementia and dementia with Lewy bodies (n = 105), VaD vascular dementia (n = 22).
Fig. 2 Effect sizes of neurodegenerative disorders as compared to amyloid-negative cognitively unimpaired controls, Parkinson’s disease and Alzheimer’s disease. Effect sizes (Hedges’s g) of different neurodegenerative disorders as compared to amyloid-negative cognitively unimpaired controls (A n = 403), Parkinson’s disease (B n = 311), and Alzheimer’s disease (C n = 236). The bars represent the mean effect size for the cohort, whereas the error bars represent the standard deviation of effect size when considering the KCL and Lund cohorts separately. Those without error bars (e.g., VaD) are only included in one cohort. AD Alzheimer’s disease (n = 236), ALS amyotrophic lateral sclerosis (n = 50), CU Aβ− cognitively unimpaired without Aβ pathology (n = 403), CBS/PSP corticobasal syndrome and progressive supranuclear palsy (n = 43), depression (n = 37), DS Down syndrome (n = 29), DSAD Down syndrome Alzheimer’s disease (n = 12), EOAD early-onset Alzheimer’s disease (n = 82), FTD frontotemporal dementia (n = 204), MCI Aβ− mild cognitive impairment without Aβ pathology (n = 170), MCI Aβ + mild cognitive impairment with Aβ pathology (n = 196), MSA multiple system atrophy (n = 29), PD Parkinson’s disease (n = 311), PDD/DLB Parkinson’s disease dementia and dementia with Lewy bodies (n = 105), VaD vascular dementia (n = 22).CC BY · PubMed Central
Fig. 3 The diagnsotic accuracy of plasma NfL in neurodegenerative disorders. Heatmaps to demonstrate the accuracy (AUC) of plasma NfL to distinguish CU and neurodegenerative disorders in the KCL (A) and Lund (B) cohorts. Heatmaps tables that demonstrate sensitivity, specificity, and 95% CI of AUC displayed in the Supplementary Tables 4–5 and Supplementary Fig. 4. AD Alzheimer’s disease, ALS amyotrophic lateral sclerosis, CU Aβ− cognitively unimpaired without Aβ pathology, CU Aβ+ cognitively unimpaired with Aβ pathology, CBS/PSP corticobasal syndrome and progressive supranuclear palsy, DS Down syndrome, DSAD Down syndrome Alzheimer’s disease, EOAD early-onset Alzheimer’s disease, FTD frontotemporal dementia, MCI Aβ− mild cognitive impairment without Aβ pathology, MCI Aβ+ mild cognitive impairment with Aβ pathology, MSA multiple system atrophy, PD Parkinson’s disease, PDD/DLB Parkinson’s disease dementia and dementia with Lewy bodies, SCD Aβ− subjective cognitive decline without Aβ pathology, SCD Aβ+ subjective cognitive decline with Aβ pathology, VaD vascular dementia.
Fig. 3 The diagnsotic accuracy of plasma NfL in neurodegenerative disorders. Heatmaps to demonstrate the accuracy (AUC) of plasma NfL to distinguish CU and neurodegenerative disorders in the KCL (A) and Lund (B) cohorts. Heatmaps tables that demonstrate sensitivity, specificity, and 95% CI of AUC displayed in the Supplementary Tables 4–5 and Supplementary Fig. 4. AD Alzheimer’s disease, ALS amyotrophic lateral sclerosis, CU Aβ− cognitively unimpaired without Aβ pathology, CU Aβ+ cognitively unimpaired with Aβ pathology, CBS/PSP corticobasal syndrome and progressive supranuclear palsy, DS Down syndrome, DSAD Down syndrome Alzheimer’s disease, EOAD early-onset Alzheimer’s disease, FTD frontotemporal dementia, MCI Aβ− mild cognitive impairment without Aβ pathology, MCI Aβ+ mild cognitive impairment with Aβ pathology, MSA multiple system atrophy, PD Parkinson’s disease, PDD/DLB Parkinson’s disease dementia and dementia with Lewy bodies, SCD Aβ− subjective cognitive decline without Aβ pathology, SCD Aβ+ subjective cognitive decline with Aβ pathology, VaD vascular dementia.CC BY · PubMed Central
Fig. 4 The diagnsotic accuracy of plasma NfL in identifying neurodegenerative disorders from controls (young/old) and depression. The performance of plasma neurofilament light (NfL) to identify neurodegenerative disorders from controls (CU and SCD) > 65 years of age (A), controls (CU and SCD) < 65 years of age (B), and depression (C).
Fig. 4 The diagnsotic accuracy of plasma NfL in identifying neurodegenerative disorders from controls (young/old) and depression. The performance of plasma neurofilament light (NfL) to identify neurodegenerative disorders from controls (CU and SCD) > 65 years of age (A), controls (CU and SCD) < 65 years of age (B), and depression (C).CC BY · PubMed Central
Fig. 5 The performance of plasma NfL concentration cutoffs to identify neurodegenerative disorders of all ages. The performance of plasma neurofilament light (NfL) concentration cutoffs to identify neurodegenerative disorders in KCL (A) and Lund (B). AD Alzheimer’s disease, ALS amyotrophic lateral sclerosis, CBS corticobasal syndrome, DLB dementia with Lewy bodies, DS Down syndrome, DSAD Down syndrome Alzheimer’s disease, EOAD early-onset Alzheimer’s disease, FTD frontotemporal dementia. MCI mild cognitive impairment, MSA multiple system atrophy, PD Parkinson’s disease, PDD Parkinson’s disease dementia, PSP progressive supranuclear palsy, SCD subjective cognitive decline, VaD vascular dementia.
Fig. 5 The performance of plasma NfL concentration cutoffs to identify neurodegenerative disorders of all ages. The performance of plasma neurofilament light (NfL) concentration cutoffs to identify neurodegenerative disorders in KCL (A) and Lund (B). AD Alzheimer’s disease, ALS amyotrophic lateral sclerosis, CBS corticobasal syndrome, DLB dementia with Lewy bodies, DS Down syndrome, DSAD Down syndrome Alzheimer’s disease, EOAD early-onset Alzheimer’s disease, FTD frontotemporal dementia. MCI mild cognitive impairment, MSA multiple system atrophy, PD Parkinson’s disease, PDD Parkinson’s disease dementia, PSP progressive supranuclear palsy, SCD subjective cognitive decline, VaD vascular dementia.CC BY · PubMed Central
Fig. 6 The performance of plasma NfL concentration cutoffs to identify neurodegenerative disorders in >65 and <65 years. The performance of plasma neurofilament light (NfL) concentration cutoffs to identify neurodegenerative disorders in >65 (A) and <65 (B). The KCL and Lund cohorts are combined for this analysis. AD Alzheimer’s disease, ALS amyotrophic lateral sclerosis, CBS corticobasal syndrome, DLB dementia with Lewy bodies, DS Down syndrome, DSAD Down syndrome Alzheimer’s disease, EOAD early-onset Alzheimer’s disease, FTD frontotemporal dementia. MCI mild cognitive impairment, MSA multiple system atrophy, PD Parkinson’s disease, PDD Parkinson’s disease dementia, PSP progressive supranuclear palsy, SCD subjective cognitive decline, VaD vascular dementia.
Fig. 6 The performance of plasma NfL concentration cutoffs to identify neurodegenerative disorders in >65 and <65 years. The performance of plasma neurofilament light (NfL) concentration cutoffs to identify neurodegenerative disorders in >65 (A) and <65 (B). The KCL and Lund cohorts are combined for this analysis. AD Alzheimer’s disease, ALS amyotrophic lateral sclerosis, CBS corticobasal syndrome, DLB dementia with Lewy bodies, DS Down syndrome, DSAD Down syndrome Alzheimer’s disease, EOAD early-onset Alzheimer’s disease, FTD frontotemporal dementia. MCI mild cognitive impairment, MSA multiple system atrophy, PD Parkinson’s disease, PDD Parkinson’s disease dementia, PSP progressive supranuclear palsy, SCD subjective cognitive decline, VaD vascular dementia.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Research works printed but not linked: 1

  1. Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. J. Am. Med. Assoc. 324, 772–781, https://doi.org/10.1001/jama.2020.12134 (2020). · DOI · Paper page

Cited by

See all 606

Metadata

Authors
Ashton, N. J., Janelidze, S., Al Khleifat, A., Leuzy, A., van der Ende, E. L., Karikari, T. K., Benedet, A. L., Pascoal, T. A., Lleó, A., Parnetti, L., Galimberti, D., Bonanni, L., Pilotto, A., Padovani, A., Lycke, J., Novakova, L., Axelsson, M., Velayudhan, L., Rabinovici, G. D., Miller, B., Pariante, C., Nikkheslat, N., Resnick, S. M., Thambisetty, M., Schöll, M., Fernández-Eulate, G., Gil-Bea, F. J., López de Munain, A., Al-Chalabi, A., Rosa-Neto, P., Strydom, A., Svenningsson, P., Stomrud, E., Santillo, A., Aarsland, D., van Swieten, J. C., Palmqvist, S., Zetterberg, H., Blennow, K., Hye, A., & Hansson, O.
Affiliations
  • King's College London (GB)
  • Lund University (SE)
  • University of Gothenburg (SE)
  • Montreal Neurological Institute and Hospital (CA)
  • Instituto de Salud Carlos III (ES)
  • University of Perugia (IT)
  • University of Milan (IT)
  • University of Chieti-Pescara (IT)
  • Fondazione Europea Ricerca Biomedica (IT)
  • University of Brescia (IT)
  • Sahlgrenska University Hospital (SE)
  • University of Leicester (GB)
  • University of California, San Francisco (US)
  • National Institutes of Health (US)
  • UCL Queen Square Institute of Neurology (GB)
Corresponding author
  • Ashton, Nicholas J.
  • Hansson, Oskar
Venue
Nature Communications
Published
2021-06-07
Volume
12
Issue
1
Pages
3400-3400
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3167068736
Cited by
545
References
69
Citations by year
2026: 74 · 2025: 116 · 2024: 125 · 2023: 102 · 2022: 92 · 2021: 35
FWCI
65.23
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (publishedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • Parkinson Research Foundation
  • Eli Lilly and Company
  • Sanofi
  • Biogen
  • Alexion Pharmaceuticals
  • Torsten Söderbergs Stiftelse
  • South London and Maudsley NHS Foundation Trust (MR/L501529/1, ES/L008238/1, 633413)
  • Wellcome Trust (MR/S005145/1, FP7/2007–2013, MR/R024901/1, 098330, 098330/Z/12/Z)
  • Health Research Board (JPI-JPND-2017-1)
  • EU Joint Programme – Neurodegenerative Disease Research (MR/L501529/1)
  • Cytokinetics
  • Australian Government
  • Apellis Pharmaceuticals
  • National Institute for Health and Care Research (ES/L008238/1, FP7/2007–2013, MR/L501529/1, NIHR202421)
  • Motor Neurone Disease Association (ALCHALABI-TALBOT/APR14/926-794, 633413, 259867, 772376, ALCHALABI-DOBSON/APR14/829-791, MR/L501529/1, Al-Chalabi/Apr19/870-791, FP7/2007-2013, ES/L008238/1)
  • King's College London
  • European Commission (2007–2013, FP7 2007-2013, HORIZON2020, H2020, FP7/2007, H2020-PHC-2014, 633413, H2020-PHC, 772376, 259867)
  • Agence Nationale de la Recherche (ANR-18-COEN-0002, ANR-17-JPCD-0001)
  • Stiftelsen för Strategisk Forskning
  • Lunds Universitet
  • Kommunfullmäktige, Stockholms Stad
  • Hjärnfonden
  • Knut och Alice Wallenbergs Stiftelse (681712)
  • Vetenskapsrådet (FP7/2007-2013, 681712, 02532, 2018-, ALFGBG-720931, 2018-02532)
  • Göteborgs Universitet
  • Alzheimerfonden
  • Skånes universitetssjukhus
  • Marcus och Amalia Wallenbergs minnesfond
  • Mitsubishi Tanabe Pharma Corporation
  • UK Dementia Research Institute
  • Demensfonden
  • National Institutes of Health (FP7/2007-2013, 2018-02532, H2020)
  • Parkinsonfonden
  • Horizon 2020 Framework Programme (FP7/2007-2013, 633413, 772376, H2020-PHC-2014)
  • Sanofi Genzyme
  • Avid Radiopharmaceuticals
  • NIHR Maudsley Biomedical Research Centre (ES/L008238/1, MR/L501529/1, 633413)
  • Medical Research Council (FP7/20072013, 259867, ES/L008238/1, MRC S011277/1, MR/S011277/1, MR/S005145/1, MR/R024901/1, MR/R024804/1, MR/L501529/1)
  • Economic and Social Research Council (ES/L008238/1, L008238, MR/L501529/1, 633413, FP7/2007-2013)
  • National Institute on Aging (P30AG066507)
  • H2020 European Research Council (681712)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
plasma neurofilament light, neurodegeneration biomarkers, neurodegenerative diseases, atypical parkinsonism, Down syndrome, dementia, depression, frontotemporal dementia, amyotrophic lateral sclerosis, diagnostic accuracy, neurofilaments
MeSH terms
Age Factors, Aged, Depression, Down Syndrome, False Positive Reactions, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Reference Values, Sex Factors, Cohort Studies, Biomarkers, Neurofilament Proteins, Neurodegenerative Diseases, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A multicentre validation study of the diagnostic value of plasma neurofilament light. https://app.cochat.ai/papers/10.1038/s41467-021-23620-z
The paper
Ashton, N. J., Janelidze, S., Al Khleifat, A., Leuzy, A., van der Ende, E. L., Karikari, T. K., Benedet, A. L., Pascoal, T. A., Lleó, A., Parnetti, L., Galimberti, D., Bonanni, L., Pilotto, A., Padovani, A., Lycke, J., Novakova, L., Axelsson, M., Velayudhan, L., Rabinovici, G. D., . . . Hansson, O. (2021). A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications. https://doi.org/10.1038/s41467-021-23620-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.